Genetic testing in PAH: assessing clinical risk and prognostic significance of mutations

Back

HFA Premium Access

Genetic testing in PAH: assessing clinical risk and prognostic significance of mutations

Session: Myocardial disease - clinical 1

Topic: Pulmonary Hypertension

Speaker: Doctor M. Vilela (Lisbon, PT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Marta Vilela

Hospital De Santa Maria, Lisbon (Portugal)

0 follower

7 more presentations in this session

Relationship between dynamics of cardiac sympathetic innervation, assessed with 123I-MIBG SPECT, exercise capacity and left ventricular reverse remodelling in dilated cardiomyopathy

Speaker: Doctor E. Dziewiecka (Krakow, PL)

The genetic architecture of dilated cardiomyopathy in Hungary: analysis of 135 patients with a panel of 98 genes

Speaker: Doctor H. Takacs (Szeged, HU)

Prevalence and predictors of normotensive cardiogenic shock in intermediate-high risk pulmonary embolism.

Speaker: Doctor B. Lacerda Teixeira (Lisbon, PT)

Hyponatremia as a predictor of short-term mortality in patients with pulmonary embolism

Speaker: Doctor J. Gouveia Fiuza (Viseu, PT)

PERFORM score: a predictive prognostic tool for anticipating the requirement for fibrinolysis in pulmonary embolism

Speaker: Doctor M. Duarte Almeida (Viseu, PT)

Access the full session

Myocardial disease - clinical 1

Speakers: Doctor M. Vilela, Doctor E. Dziewiecka, Doctor H. Takacs, Doctor B. Lacerda Teixeira, Doctor J. Gouveia Fiuza...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources